Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation.
Fiche du document
2014
- doi: 10.1371/journal.pone.0091398
- issn: 1932-6203
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0091398
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/24622012
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1932-6203
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_AFB9689A0B8A4
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Tsʻeu Tzʻu Ci Tse Cardiac failure Failure, Heart Insufficiency, Cardiac Cardiac insufficiencyCiter ce document
J.C. Lega et al., « Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation. », Serveur académique Lausannois, ID : 10.1371/journal.pone.0091398
Métriques
Partage / Export
Résumé
AIMS: The well-known limitations of vitamin K antagonists (VKA) led to development of new oral anticoagulants (NOAC) in non-valvular atrial fibrillation (NVAF). The aim of this meta-analysis was to determine the consistency of treatment effects of NOAC irrespective of age, comorbidities, or prior VKA exposure. METHODS AND RESULTS: All randomized, controlled phase III trials comparing NOAC to VKA up to October 2012 were eligible provided their results (stroke/systemic embolism (SSE) and major bleeding (MB)) were reported according to age (≤ or >75 years), renal function, CHADS2 score, presence of diabetes mellitus or heart failure, prior VKA use or previous cerebrovascular events. Interactions were considered significant at p